Hepatitis clinical trials
The registry lists 343 studies for Hepatitis across more than 10 countries. 51 are recruiting or about to start. 101 of them are mainly about Hepatitis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 12 narrower conditions too, such as Hepatitis C: 4,596 studies, 460 open.
Get an email when these change. Save the Hepatitis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Gilead Sciences (25) · GlaxoSmithKline (11) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (11) · Vir Biotechnology, Inc. (9) · Dynavax Technologies Corporation (9) · National Institute of Allergy and Infectious Diseases (NIAID) (8) · Kirby Institute (5) · Merck Sharp & Dohme LLC (5)
What is being tested here
Drugs under test in Hepatitis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Drug classes tested here Reverse transcriptase inhibitors 8 · Integrase inhibitors 4
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide · Phase 3 · Vir Biotechnology, Inc.
- Sep 2027Phase Ⅲ Clinical Trial of an Inactivated Hepatitis A Vaccine · Phase 3 · Sinovac Biotech Co., Ltd
- Nov 2027Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) · Phase 3 · Bausch Health Americas, Inc.
- Nov 2026A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection · Vir Biotechnology, Inc.
- Nov 2026A Multicenter Prospective Clinical Cohort Study on the Pathogen Spectrum of Severe Hepatitis (Liver Failure) Complicated With Infection · Zhejiang University
- Dec 2026To Evaluate the Efficacy and Safety of TYNADOTE® in the Treatment of Acetaminophen Overdose · Sinew Pharma Inc.
- Dec 2026Effect of Alpha-1 Antitrypsin Supplementation on Alcohol-Associated Hepatitis · Medical University Innsbruck
- Dec 2026Is Negativity of Autoantibodies a Marker of Severity in Auto-immune Hepatitis? · Centre Hospitalier Universitaire de la Guadeloupe
- Jan 2027Specific Biomarkers of Immune-mediated Hepatitis Secondary to Immune Checkpoint Inhibitors · University Hospital, Montpellier
- May 2027Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions · AusperBio Therapeutics Inc.
Who these studies take
Of the 36 Hepatitis studies recruiting now, 23 (64%) set no upper age limit and 11 (31%) stop at 75 or younger. 6 (17%) take children under 18. 2 (6%) are for women only and 0 (0%) for men only; 8 (22%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 4 (11%) | 3 (8%) |
| 18 | 33 (92%) | 31 (86%) |
| 30 | 35 (97%) | 33 (92%) |
| 40 | 35 (97%) | 33 (92%) |
| 50 | 35 (97%) | 33 (92%) |
| 65 | 33 (92%) | 32 (89%) |
| 75 | 27 (75%) | 26 (72%) |
| 85 | 25 (69%) | 24 (67%) |
Across all 343 studies, recruiting or not: 45% stop at 75 or younger and 30% at 65; 21% take children; 3% are for women only and 3% for men only; 27% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Hepatitis studies take
Of 23 phase 3 interventional studies under Hepatitis, half reached primary completion within 26 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 2 | 30 mo24–40 · 22 studies | — | — |
| Phase 3 | 26 mo20–38 · 23 studies | — | — |
| Interventional, no phase | 26 mo15–39 · 33 studies | — | — |
| Observational | 59 mo37–195 · 36 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 11, 2026.
Started recruiting1
Newly registered1
- A Study of LY3981314 in Participants With Autoimmune HepatitisNov 10, 2026NCT07928219
Studies
Recruiting first, then most recently updated. Showing 50 of 343. Browse all 343 → or search them.
- A Study of LY3981314 in Participants With Autoimmune HepatitisNot yet recruitingNCT07928219Phase 11 country
- Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)RecruitingNCT07631637Phase 23 countries
- Conventional Ultrasound Versus Remote Ultraportable ulTrasound in the Context of Viral HepatitisRecruitingNCT065719811 country
- Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe RegionsRecruitingNCT07654283Phase 26 countries
- Evaluation of Non-Invasive Tests for Metabolic Liver DiseaseRecruitingNCT071227001 country
- Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)RecruitingNCT07428538Phase 31 country
- Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific RegionRecruitingNCT07370207Phase 27 countries
- Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income CountriesRecruitingNCT063951293 countries
- Effect of Alpha-1 Antitrypsin Supplementation on Alcohol-Associated HepatitisRecruitingNCT06582329Phase 21 country
- Blood Collection Biorepository for Liver Disease ResearchRecruitingNCT030250741 country
- Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor TherapyRecruitingNCT07663422Phase 21 country
- Phase Ⅲ Clinical Trial of an Inactivated Hepatitis A VaccineRecruitingNCT07793227Phase 31 country
- Severe Hepatitis Intervention With Emapalumab for Liver DiseaseNot yet recruitingNCT07744919Phase 21 country
- Developing an HIV Disclosure Intervention for Men in UgandaNot yet recruitingNCT05771519Not applicable1 country
- Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) TrialRecruitingNCT07060638Phase 21 country
- Prospective Cohort of Immune Checkpoint Inhibitor-induced HepatitisRecruitingNCT068644811 country
- PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid ExposureNot yet recruitingNCT07619898Phase 2
- HIBOC = Hepatic Imaging Biomarkers in Obese ChildrenEnrolling by invitationNCT064632231 country
- IMARA for Black Male Caregivers and Girls Empowerment (IMAGE)RecruitingNCT06266416Not applicable1 country
- Checkpoint Inhibitor-induced Liver InjuryRecruitingNCT044765631 country
- Steroid Sparing in Immune Related Hepatitis (irH)RecruitingNCT05345847Not applicable1 country
- ePro Diary - HDV ( MACROLIVER )RecruitingNCT074427601 country
- "Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort"Not yet recruitingNCT074129771 country
- Sexual Health Access at Retail Pharmacies: Advancing Pharmacy-based Delivery of Primary STI and HIV Prevention for Cisgender WomenNot yet recruitingNCT07361926Not applicable
- Specific Biomarkers of Immune-mediated Hepatitis Secondary to Immune Checkpoint InhibitorsRecruitingNCT064709971 country
- Characterization of the Intrahepatic Inflammatory Microenvironment in Patients With Non-alcoholic SteatohepatitisRecruitingNCT06152250Not applicable1 country
- Safety and Tolerability of NTR-101 in Patients With Acute Alcohol-Associated HepatitisNot yet recruitingNCT06750588Phase 11 country
- Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and Vulnerable Populations, in Non-conventional Structures "Outside the Walls" by Dual Screening Method RTDs and FibroScan®RecruitingNCT069048201 country
- Improving Perinatal Outcomes Among Kenyan Pregnant Women With an Integrated STI Testing ModelRecruitingNCT06203951Not applicable1 country
- Immunity With Acute Hepatits ANot yet recruitingNCT06942962
- Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.RecruitingNCT004049891 country
- The Safety ,Tolerability and Efficacy Study of HepaCure in Chinese Subjects with Acute-On-Chronic Liver FailureRecruitingNCT05989958Phase 1/21 country
- LivQ-box® Parameters in the Diagnosis of Liver InflammationRecruitingNCT068027311 country
- Acute Hepatitis in PediatricsRecruitingNCT067612611 country
- Is Negativity of Autoantibodies a Marker of Severity in Auto-immune Hepatitis?RecruitingNCT067612091 country
- Research on the Monitoring, Pathogen Screening, and Diagnostic System for Unexplained and Newly Emerging Acute HepatitisNot yet recruitingNCT066531401 country
- Risk Factors and Frequency of Acute Idiopathic Hepatitis in Children at Assiut Children HospitalNot yet recruitingNCT06454760
- Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research InitiativesRecruitingNCT056352661 country
- A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy VolunteersRecruitingNCT05563961Not applicable1 country
- A Multicenter Prospective Clinical Cohort Study on the Pathogen Spectrum of Severe Hepatitis (Liver Failure) Complicated With InfectionNot yet recruitingNCT06272071
- Immune Cell Dysfunction in Severe Alcoholic HepatitisRecruitingNCT022751951 country
- To Evaluate the Efficacy and Safety of TYNADOTE® in the Treatment of Acetaminophen OverdoseRecruitingNCT05557448Phase 21 country
- Validation of SMS Protocol for HCC Screening in High-risk PatientsEnrolling by invitationNCT054291901 country
- Effectiveness of Ultrasound in Liver Stiffness and Fat QuantificationRecruitingNCT06111859Not applicable1 country
- The Living With a Long-Term Condition StudyRecruitingNCT060722871 country
- Agreement and Reliability of Transient ElastographyRecruitingNCT056867851 country
- Seville Cohort of People at Substantial Risk for HIV Infection on Pre-exposure ProphylaxisEnrolling by invitationNCT054925651 country
- Epidemiology of Occult Hepatitis C Virus Infection in Patients Born Before 1969 in the Hospital Setting: a Spontaneous Opportunistic Screening Initiative.Not yet recruitingNCT05813691
- A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Liver CancerRecruitingNCT057194801 country
- Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related HepatitisRecruitingNCT04810156Phase 21 country